SLC22A1 and obesity disorder: The other study is a pharmacokinetic approach in children with obesity, and could not identify any influence of genetic variants from the OCT1 and multidrug and toxin extrusion protein 1 (MATE1) transporters on the pharmacokinetics of metformin [10].